Shorter vs longer oxaliplatin infusions for gut cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study compares giving oxaliplatin by IV for 2 hours versus 6 hours, along with the standard FOLFOX6 chemotherapy. It aims to see if the shorter infusion works as well and is manageable for people with gastrointestinal cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed gastrointestinal cancer (stomach, colon, rectum, or similar).
- Your cancer can be measured (if advanced/metastatic) or you’re planning more than 4 cycles of FOLFOX-containing chemo.
- You can do daily activities fairly well (ECOG 0 to 2).
- Your blood counts are strong enough for chemo: neutrophils (ANC) at least 1,500 and platelets at least 75,000.
- Your kidneys are working well enough (creatinine clearance above 30).
- You do not have nerve damage from treatment before starting (no grade 2 or worse peripheral neuropathy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving oxaliplatin for a shorter or longer time works best after curative surgery for stage II–III stomach (or stomach–esophagus junction) cancer. It aims to improve outcomes while balancing side effects from chemotherapy.
This trial tests a modified version of a common chemotherapy combination (capecitabine and oxaliplatin) for people with gastrointestinal cancers who are not expected to be cured. It aims to see if a simpler treatment schedule can be just as effective while reducing side effects.
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
This trial tests whether adjusting the dose of chemotherapy drugs (5-FU or capecitabine plus oxaliplatin) based on a liver enzyme test can improve safety and effectiveness for people with gastrointestinal cancer who are starting this type of chemo for the first time.
This Phase 2 trial studies whether reusing the chemotherapy drug oxaliplatin is safe for people with gastrointestinal (stomach or bowel) tumors who need oxaliplatin. You may be able to take the drug again under close monitoring to see how well it works and how safe it is, including if you previously had an allergic reaction.
This trial compares two chemotherapy schedules around stomach cancer surgery: giving chemo before and after surgery (FLOT) versus giving chemo after surgery (XELOX). It’s meant to see which plan works better and is easier to tolerate for locally advanced disease that has not spread.
Hear when a new Malignant Digestive System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.